# Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

> **NCT06659029** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 442 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Anifrolumab

## Key facts

- **NCT ID:** NCT06659029
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2031-04-15
- **Final completion:** 2031-04-15
- **Target enrollment:** 442 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659029, "Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06659029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*